Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. (BBNX) from its SEC filings: 2025 revenue $100.3 million (+54% vs the year before), net margin -73%, free cash flow -$56.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $100.3 million |
| Revenue growth | +54% |
| Net income | -$73.2 million |
| Net margin | -73.0% |
| Free cash flow | -$56.2 million |
| Diluted EPS | $-1.81 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +38% |
| Cash | $44.3 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.